Neumora Therapeutics, Inc.

NMRA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 30.3%, free cash flow grew 24.5% and total debt rose 172.0%, each against the same quarter a year earlier.

0.47 0.04 +9.30%
Market cap
$80.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
177.08 190.54 153.43 124.87
Total non-current assets
0.75 0.51 0.44 0.38
Total Assets
177.83 191.05 153.88 125.25
Total current liabilities
25.84 32.45 30.12 27.78
Total non-current liabilities
19.83 54.73 53.08 52.95
Total liabilities
45.67 87.18 83.20 80.73
Common Equity (Total)
132.16 103.87 70.68 44.52
Shareholders Equity (Total)
132.16 103.87 70.68 44.52
Total Debt
19.56 54.53 52.96 52.91

Show all line items

In millions of $ except per-share values · columns are period end dates